The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially eliminating the need for complex lab-based manufacturing. Early results show rapid ...

Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...

Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

A breakthrough in CAR-T therapy may allow cancer treatment with a single injection, cutting costs and making care more available.

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as ...

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...

A new strategy strengthens the bond between the T cell and a target tumor cell, improving the cytotoxic function of the T cell.